US Edition
Clearmind adds leading Israeli clinical site to ongoing trial of CMND-100 in AUD - BioTuesdays
Summary by biotuesdays.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Clearmind adds leading Israeli clinical site to ongoing trial of CMND-100 in AUD - BioTuesdays
Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that it has added Tel Aviv Sourasky Medical Center (TASMC) to the list of clinical sites for its ongoing Phase 1/2a trial evaluating CMND-100—a proprietary MEAI-based oral drug candidate—for the treatment of alcohol use disorder (AUD). According to Clearmind, this expansion follows the recent enrollment of the trial’s first patient, announced on June 5, 2025, marking a significant milest…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
